Most Clicked StoriesMore >


UK halts routine drug-safety compliance reporting

DIA Global SmartBrief | Jul 28, 2016

The UK's Medicines and Healthcare Products Regulatory Agency says drugmakers may cease submitting regular drug-safety surveillance compliance reports unless the agency specifically calls for them. Regulatory Focus (07/26)


EMA says some generic-drug-makers used unreliable studies

DIA Global SmartBrief | Jul 26, 2016

EMA to update first-in-human trial guidelines

DIA Global SmartBrief | Jul 26, 2016

Final guidance on adaptive design use released by FDA

DIA Global SmartBrief | Jul 28, 2016

Advance thought leadership in the new July Journal

DIA Global SmartBrief | Jul 28, 2016

FDA issues guidance on real-world data use for device regulatory decisions

DIA Global SmartBrief | Jul 28, 2016

FDA approves revised label for fluoroquinolone antibiotics

DIA Global SmartBrief | Jul 28, 2016

Explore the June Global Forum

DIA Global SmartBrief | Jul 26, 2016

China to launch human trial using CRISPR-edited genes in Aug.

DIA Global SmartBrief | Jul 26, 2016

Draft guidance on UDI compliance issued by FDA

DIA Global SmartBrief | Jul 28, 2016


Find DIA Global SmartBrief Issues by Date:



DIA News More >


Advance thought leadership in the new July Journal

DIA Global SmartBrief | Jul 28, 2016

Explore the June Global Forum

DIA Global SmartBrief | Jul 26, 2016

Raise your profile and develop your horizons

DIA Global SmartBrief | Jul 21, 2016

Take the next step -- DIA Career Center

DIA Global SmartBrief | Jul 21, 2016




Sign up for DIA Global SmartBrief



Designed specifically for the global drug development professional, the DIA Global SmartBrief is a FREE, twice weekly e-mail newsletter. By providing the latest need-to-know industry news and information, the DIA Global SmartBrief saves you time and keeps you smart. Learn more